Fenofibrate/simvastatin
| Combination of | |
|---|---|
| Fenofibrate | Fibrate |
| Simvastatin | Statin |
| Clinical data | |
| Trade names | Cholib |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]
It was approved for use in the European Union in August 2013.[1]
Medical uses
[edit]Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]
Adverse effects
[edit]References
[edit]- ^ a b c d e "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Archived from the original on 12 November 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
Further reading
[edit]- Filippatos TD, Elisaf MS (2015). "Safety considerations with fenofibrate/simvastatin combination". Expert Opin Drug Saf. 14 (9): 1481–93. doi:10.1517/14740338.2015.1056778. PMID 26134595. S2CID 207488283.
- Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, et al. (2017). "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy". Vasc Health Risk Manag. 13: 29–41. doi:10.2147/VHRM.S95044. PMC 5317328. PMID 28243111.
{{cite journal}}: CS1 maint: overridden setting (link)
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |